Quick Answer
Esperion Therapeutics, Inc. reported Earnings Per Share Diluted of $0.11 (loss) per share for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +60.7% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Esperion Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 96.9%.
- Historical annual values: Fiscal year 2025: $0.11 (loss) per share | Fiscal year 2024: $0.28 (loss) per share | Fiscal year 2023: $2.03 (loss) per share | Fiscal year 2022: $3.52 (loss) per share | Fiscal year 2021: $9.31 (loss) per share | Fiscal year 2020: $5.23 (loss) per share | Fiscal year 2019: $3.59 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: